Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Imunon, Inc. (IMNN) Form 4: Director Donald P. Braun reported two transactions dated 08/04/2025 following the company’s 1-for-15 reverse split completed 07/25/2025.
- Equity grant in lieu of cash fees: 2,040 common shares acquired at the split-adjusted closing price of $9.20, increasing Braun’s direct holdings to 3,747 shares.
- New stock option: right to purchase 250 shares at an exercise price of $9.20; 50% vests immediately, 25% after one year, and the remaining 25% after two years, expiring 08/04/2035.
Post-transaction, Braun also holds 250 options in addition to the common shares. The share acquisition represents payment of board fees in stock rather than cash, signalling alignment with shareholder interests, though the dollar value (<≈ $18.8 k) is modest relative to market capitalization. No sales were disclosed.
Event summary: On August 5, 2025 Imunon, Inc. (IMNN) furnished a press release reporting financial results for the quarter ended June 30, 2025 as Exhibit 99.1. The company had announced on July 29, 2025 that it would hold a conference call on August 5, 2025 to discuss those results; the call was webcast at http://www.imunon.com.
The 8-K clarifies the furnished information is not "filed" under Section 18 of the Exchange Act and contains forward-looking statements subject to a cautionary note in the press release. Exhibits listed are 99.1 (press release) and 104 (Interactive Data). The report is signed by CFO Kimberly Graper and lists principal offices at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311 with phone (609) 896-9100.
Imunon, Inc. filed a Form 8-K on 28 Jul 2025 reporting that its Board of Directors has approved a 15% stock dividend, equal to 0.15 additional shares for every outstanding share and each common-stock equivalent with dividend rights. The Board set 7 Aug 2025 as the record date and 21 Aug 2025 as the payment date. Exhibit 99.1 contains the related press release; no other material events, financial results, or transactions were disclosed. The information in the exhibit is furnished, not filed, under the Exchange Act.